Browse Studies — Arctuva

Phase 2

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philad…

Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential Thrombocythemia+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06661915

Phase 2

A Phase 2 Trial Investigating the Addition of Pacritinib to a Hypomethylating Agent as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic …

Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative Neoplasm

Estimated

~$10 – $6,250

University of WashingtonNCT07148947

The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).

The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of …

Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more